HEARTBEAT.BIO
HeartBeat.bio is a privately funded drug discovery company focusing on the development of a high-throughput 3D screening platform for heart failure and cardiomyopathies.
HEARTBEAT.BIO
Social Links:
Industry:
Biotechnology Medical
Founded:
2021-01-01
Address:
Vienna, Wien, Austria
Country:
Austria
Website Url:
http://www.heartbeat-bio.eu
Status:
Active
Email Addresses:
[email protected]
Total Funding:
1.5 M EUR
Technology used in webpage:
Domain Not Resolving
Similar Organizations
Kinetic Discovery Ltd.
Kinetic Discovery Ltd offers drug discovery services as hit identification, confirmation and validation.
leadXpro AG
LeadXpro is a lead discovery company focusing on membrane protein drug targets.
NMD Pharma
NMD Pharma is a small molecule drug discovery company that develops novel treatments of neuromuscular disorders.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
Current Employees Featured
Founder
Investors List
red-stars.com
red-stars.com investment in Seed Round - HeartBeat.bio
More informations about "HeartBeat.bio"
HeartBeat.bio – REINVENTING CARDIAC DRUG …
HeartBeat. bio . Our mission is to radically change the paradigm of cardiac drug development by converging unique human organoid technologies, hardware engineering, and artificial intelligence. HeartBeat.bio AG Vienna Biocenter 6 …See details»
Company – HeartBeat.bio
HeartBeat.bio is a drug discovery company dedicated to developing a high-throughput human organoid screening platform for cardiac drug discovery.The technology platform is built on the …See details»
HeartBeat.bio - Crunchbase Company Profile & Funding
HeartBeat.bio may be growing as it has successfully raised €4.5 million in a Pre-Series A funding round, which is a significant financial milestone for the company. This capital infusion is intended to support the development of their 3D human …See details»
HeartBeat.bio AG - Vienna BioCenter
Currently, HeartBeat.bio is focused on drug-induced and different sub-types of genetic cardiomyopathies, followed by programs in diabetic cardiomyopathy, myocardial infarction, …See details»
HeartBeat.bio raises € 4.5 million in Pre-Series A financing to drive ...
Vienna, Austria – 02 November 2023 – HeartBeat.bio AG, a biotech company building a highly scalable human organoid and AI-supported drug discovery platform for heart disease, today …See details»
HeartBeat.bio raises € 4.5 million in Pre-Series A …
Nov 2, 2023 Contact. Martin Kovalčík, [email protected], +420 777 472 863 About HeartBeat.bio AG (HeartBeat.bio) HeartBeat.bio is building the worldwide first high-throughput human organoid cultivation, screening and AI-supported …See details»
HeartBeat.bio AG - Life Sciences Directory
HeartBeat.bio is an early-stage drug discovery company focused on the development of a high-throughput fully human 3D screening platform for heart diseases. The technology has the …See details»
Austrian biotech HeartBeat.bio secures €4.5M for …
Nov 2, 2023 Austrian biotech startup HeartBeat.bio has secured a € 4.5 million Pre-Series A round.. The fresh capital will fuel the completion of its cardioid drug discovery platform for proprietary and collaborative drug discovery programs …See details»
HeartBeat.bio | EU-Startups
HeartBeat.bio, based in Vienna, Austria, is a recently founded drug discovery company focusing on the development of a high-throughput 3D screening platform for heart failure and cardiomyopathy. ... https://heartbeat-bio.eu/ …See details»
HeartBeat.bio AG. (11/02/23). "Press Release: HeartBeat.bio Raises …
HeartBeat.bio AG, a biotech company building a highly scalable human organoid and AI-supported drug discovery platform for heart disease, today announced the closing of a € 4.5 …See details»
Vienna-based HeartBeat.bio raises €4.5 million to
Nov 3, 2023 HeartBeat.bio, a biotech company building a highly scalable human organoid and AI-supported drug discovery platform for heart disease, announced the closing of a €4.5 million pre-Series A round co-led by i&i Biotech Fund, …See details»
HeartBeat.bio AG to Reinvent Cardiac Drug Discovery
May 4, 2021 HeartBeat.bio has signed an exclusive license and collaboration agreement with IMBA and will closely cooperate with the research group of Sasha Mendjan to further develop …See details»
HeartBeat.bio Company Profile 2024: Valuation, Funding
HeartBeat.bio General Information Description. Operator of a human-centric drug discovery platform intended to develop first-in-class therapies for heart failure. The company generates …See details»
HeartBeat.bio collaborates with Boehringer Ingelheim to …
VIENNA, Austria – 5 October 2022 – HeartBeat.bio AG has entered a collaboration with Boehringer Ingelheim for the investigation of human cardiac organoids (Cardioids) for high …See details»
€4.5 million for HeartBeat.bio: Innovating heart disease drug …
Nov 6, 2023 While cardiovascular diseases are the leading cause of death worldwide, the development of effective therapeutic options is still limited due to high failure rate in clinical …See details»
“HeartBeat.bio announces publication in Cell demonstrating the …
Vienna, 20.05.2021: “HeartBeat.bio announces publication in Cell demonstrating the power - Worldwide first self-organizing heart organoids (“cardioids”) prove to be effective as a human …See details»
HeartBeat.bio raises € 4.5 million in Pre-Series A financing to drive ...
Nov 2, 2023 HeartBeat.bio AG, a biotech company building a highly scalable human organoid and AI-supported drug discovery platform for heart disease, today announced the closing of a …See details»
HeartBeat.bio collaborates with Boehringer Ingelheim to …
Oct 5, 2022 HeartBeat.bio’s heart organoids are stem-cell derived 3D cell culture systems, which mimic the human heart physiology in a totally new way. In collaboration with Molecular …See details»
HeartBeat.bio and Molecular Devices announce collaboration to …
Sep 12, 2022 VIENNA and SAN JOSE, CA – Sept. 12 – HeartBeat.bio AG, a biotech company developing cardiac organoids (Cardioids) for drug discovery, and Molecular Devices, LLC., a …See details»
HeartBeat.bio announces publication in Cell demonstrating the …
Vienna, Austria – 20 May 2021 – HeartBeat.bio AG, a biotech company focusing on cardiac drug discovery based on heart organoids, announced today the publication of “Cardioids reveal self …See details»